At the crossroads of targeted treatment and resistance in melanoma
- PMID: 23561743
- DOI: 10.1016/S1470-2045(13)70108-6
At the crossroads of targeted treatment and resistance in melanoma
Comment on
-
Which drug, and when, for patients with BRAF-mutant melanoma?Lancet Oncol. 2013 Feb;14(2):e60-9. doi: 10.1016/S1470-2045(12)70539-9. Lancet Oncol. 2013. PMID: 23369684 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
